Sökning: WFRF:(Bonnefoi HR)
> (2010-2014) >
Phase III trial (EO...
-
Bonnefoi, HR
(författare)
Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis
- Artikel/kapitelEngelska2010
Förlag, utgivningsår, omfång ...
-
American Society of Clinical Oncology (ASCO),2010
Nummerbeteckningar
-
LIBRIS-ID:oai:prod.swepub.kib.ki.se:128455430
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:128455430URI
-
https://doi.org/10.1200/jco.2010.28.18_suppl.lba503DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:vet swepub-contenttype
-
Ämneskategori:kon swepub-publicationtype
Anmärkningar
-
LBA503 Background: Predictive markers of response to chemotherapy are lacking. Preclinical data suggest that p53 mutated tumors are resistant to anthracyclines and sensitive to taxanes. However, clinical data are contradictory. Using a functional yeast assay to detect biologically important mutations, this study tested the hypothesis that docetaxel confers a greater advantage over anthracyclines in p53 mutated tumors (mut) than p53 wild type (wt). Methods: Patients (pts) with locally advanced/inflammatory or large operable tumors were randomized to either a standard anthracycline regimen (arm A) or a taxane-based treatment (arm B). In arm A pts received 6 cycles of FEC 100, or tailored FEC + G-CSF (Swedish cohort). In arm B docetaxel (T) 100mg/m2 was given for 3 cycles, followed by 3 cycles of epirubicin 90mg/m2and T 75mg/m2 q3 weeks (T-ET). After chemotherapy, pts underwent surgery followed by radiotherapy. Endocrine therapy and/or trastuzumab were given according to each center's policy. Fresh frozen tumor biopsies were mandatory before starting chemotherapy: frozen sections were examined centrally and the p53 test was done when the invasive tumor cell content was > 20%. cDNA derived from tumor-extracted RNA was transfected into yeast (Flaman et al. PNAS 1995): tumors were deemed p53 wt when there were < 20% red colonies (background) and p53 mut > 20%. The three co-primary comparisons for the endpoint of progression-free survival (PFS) were between arms A and B in p53 mut, p53 wt, and the entire trial population, each at a p=0.02. The sample size gave sufficient power for an interaction test for outcomes between p53 mut and wt at p<0.05. Results: From April 2001 to November 2006, 1,856 patients were included. A total of 386 pts (21%) were ineligible (including 292 pts with <20% tumor cells and 67 without sample). No unexpected toxicity was observed. At the time of analysis 675 events were registered after a median follow-up time of 57 months. The results are summarized below. Conclusions: p53 is not a predictive factor of response or resistance to taxanes, although it is, as expected, prognostic (<0.001). PFS is not statistically significantly different between FEC and T-ET arms at the 2% cutoff level. [Table: see text] [Table: see text]
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Bogaerts, J
(författare)
-
Piccart, M
(författare)
-
Mauriac, L
(författare)
-
Fumoleau, P
(författare)
-
Jassem, J
(författare)
-
Becette, V
(författare)
-
Cameron, DA
(författare)
-
Bergh, J
(författare)
-
Iggo, R
(författare)
Sammanhörande titlar
-
Ingår i:JOURNAL OF CLINICAL ONCOLOGY: American Society of Clinical Oncology (ASCO)28:180732-183X1527-7755
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bonnefoi, HR
-
Bogaerts, J
-
Piccart, M
-
Mauriac, L
-
Fumoleau, P
-
Jassem, J
-
visa fler...
-
Becette, V
-
Cameron, DA
-
Bergh, J
-
Iggo, R
-
visa färre...
- Artiklar i publikationen
-
JOURNAL OF CLINI ...
- Av lärosätet
-
Karolinska Institutet